​Jessica Reed serves as Chief Executive Officer and Board Member for Diapin Therapeutics, Inc., and is an experienced Pharmaceutical Director, having led multiple successful projects including 10 INDs and 7 NDA/sNDA submissions. Key contributor to teams that have delivered five pre-clinical candidates one of which advanced to market for the treatment of cancer (dacomitinib) Vizimpro, and one that advanced to phase I, for diabetes. Advanced ten discovery projects in oncology, CNS, and metabolic disease groups, providing leadership and scientific oversight to teams of cross functional scientists. Jessica is highly engaged, with excellent project management, communication, problem solving, organizational and analytical skills. She has over 20 years of experience in the pharmaceutical industry with a proven record of accomplishment in discovery, nonclinical and clinical research projects.